UC Davis Health Ramps Up Project Lightspeed: Serves as Trial Site for Phase 2/3 BNT162 COVID-19 Vaccine Study

UC Davis Health Ramps Up Project Lightspeed Serves as Trial Site for Phase 23 BNT162 COVID-19 Vaccine Study

UC Davis Health was one of about 120 trial sites selected worldwide to participate in the Phase 2/3 stage testing of the COVID-19 vaccine candidate known as BTN162, developed by Germany’s BioNTech and Pfizer Inc. The addition of this pivotal clinical trial adds even a more significant component to the university’s response to COVID-19. Now Davis, California—near Sacramento—is hosting the major clinical trial and 200 volunteers are needed. UC Davis’ Medical Center providers diagnosed and treated the first apparent case of COVID-19 in the United States, according to their recent news release. UC Davis Health represents the hub of medical research for Sacramento, California’s capital and rapidly growing metropolis.

Uniquely Positioned

UC Davis Health, according to David Lubarsky, vice chancellor of human health sciences and chief executive officer for UC Davis Health is “uniquely positioned to help with a possible breakthrough,” contributing to this pivotal study because 1) deep clinical trials expertise, 2) ability to expedite the recruitment of study volunteers, and 3) track record of engaging with minority communities that can translate to more diverse volunteers.

The Stu...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee